Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based CompensationShares Issued
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences, Inc. (RNA) Share-based Compensation (2019 - 2025)

Avidity Biosciences' Share-based Compensation history spans 7 years, with the latest figure at $43.4 million for Q4 2025.

  • For Q4 2025, Share-based Compensation rose 206.78% year-over-year to $43.4 million; the TTM value through Dec 2025 reached $97.8 million, up 90.48%, while the annual FY2025 figure was $97.8 million, 90.48% up from the prior year.
  • Share-based Compensation reached $43.4 million in Q4 2025 per RNA's latest filing, up from $19.0 million in the prior quarter.
  • In the past five years, Share-based Compensation ranged from a high of $43.4 million in Q4 2025 to a low of $3.7 million in Q1 2021.
  • Average Share-based Compensation over 5 years is $11.6 million, with a median of $9.6 million recorded in 2023.
  • Peak YoY movement for Share-based Compensation: surged 724.28% in 2021, then increased 13.2% in 2024.
  • A 5-year view of Share-based Compensation shows it stood at $4.5 million in 2021, then skyrocketed by 61.8% to $7.3 million in 2022, then surged by 34.73% to $9.8 million in 2023, then surged by 43.76% to $14.2 million in 2024, then surged by 206.78% to $43.4 million in 2025.
  • Per Business Quant, the three most recent readings for RNA's Share-based Compensation are $43.4 million (Q4 2025), $19.0 million (Q3 2025), and $17.7 million (Q2 2025).